Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2Phase 1 2Phase NA 1Phase 1/2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 6Endocrine 2

Conditions

Low Risk Differentiated Thyroid Cancer 1Differentiated Thyroid Cancer 1

Interventions

Everolimus 8lanreotide 7Octreotide 7lutetium Lu 177 dotatate 6pasireotide 5Thyrotropin Alfa 5Mitotane 4Etoposide 4Doxorubicin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4amino-acid, glucose, and electrolyte solution 3Mifepristone 3Filgrastim 3Corlux 3Cisplatin 3Chemotherapy, Adjuvant 3Capecitabine 3Cabergoline 3vandetanib 2telotristat ethyl 2surufatinib 2ribociclib 2fluorodopa F 18 2cabozantinib 2Temozolomide 2Receptor-Like Protein Tyrosine Phosphatases, Class 2 2Lutetium-177 2Lutetium 2Leucovorin 2Iodine-131 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Iodine-131 × Endocrine × Clear all
NCT04964284 2023-10-23

Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Unknown
328 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT01837745 2023-05-17

ESTIMABL2

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Active not recruiting
776 enrolled
EndocrineHead & Neck

Low Risk Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡